-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Adult ADHD: an area lacking in clinical research?
Josep Antoni, Ramos-Quiroga & Miren Ochoa Sagues
Editorial: Clinical Investigation
-
Adult ADHD: an area lacking in clinical research?
Josep Antoni, Ramos-Quiroga & Miren Ochoa Sagues
Editorial: Clinical Investigation
-
Adult ADHD: an area lacking in clinical research?
Josep Antoni, Ramos-Quiroga & Miren Ochoa Sagues
Editorial: Clinical Investigation
-
Adult ADHD: an area lacking in clinical research?
Josep Antoni, Ramos-Quiroga & Miren Ochoa Sagues
Editorial: Clinical Investigation
-
Adult ADHD: an area lacking in clinical research?
Josep Antoni, Ramos-Quiroga & Miren Ochoa Sagues
Editorial: Clinical Investigation
-
Adult ADHD: an area lacking in clinical research?
Josep Antoni, Ramos-Quiroga & Miren Ochoa Sagues
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation